XTX Topco Ltd Raises Stock Holdings in Ardelyx, Inc. (NASDAQ:ARDX)

XTX Topco Ltd boosted its holdings in Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 369.0% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 140,467 shares of the biopharmaceutical company's stock after buying an additional 110,514 shares during the period. XTX Topco Ltd owned 0.06% of Ardelyx worth $712,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of ARDX. B. Riley Wealth Advisors Inc. boosted its holdings in shares of Ardelyx by 3.4% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 90,000 shares of the biopharmaceutical company's stock valued at $599,000 after purchasing an additional 3,000 shares during the last quarter. Swiss National Bank boosted its holdings in shares of Ardelyx by 1.0% during the 4th quarter. Swiss National Bank now owns 463,100 shares of the biopharmaceutical company's stock valued at $2,348,000 after purchasing an additional 4,800 shares during the last quarter. Orion Portfolio Solutions LLC boosted its holdings in shares of Ardelyx by 42.7% during the 4th quarter. Orion Portfolio Solutions LLC now owns 16,486 shares of the biopharmaceutical company's stock valued at $84,000 after purchasing an additional 4,933 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Ardelyx by 10.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 50,222 shares of the biopharmaceutical company's stock valued at $255,000 after purchasing an additional 4,942 shares during the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of Ardelyx by 1.9% during the 4th quarter. Rhumbline Advisers now owns 326,124 shares of the biopharmaceutical company's stock valued at $1,653,000 after purchasing an additional 6,070 shares during the last quarter. Hedge funds and other institutional investors own 58.92% of the company's stock.

Ardelyx Trading Down 0.8 %

NASDAQ ARDX traded down $0.04 during trading on Wednesday, hitting $4.77. The stock had a trading volume of 1,073,182 shares, compared to its average volume of 4,368,912. The company has a debt-to-equity ratio of 0.87, a quick ratio of 4.31 and a current ratio of 4.58. The stock has a market capitalization of $1.14 billion, a price-to-earnings ratio of -29.81 and a beta of 0.81. Ardelyx, Inc. has a one year low of $4.02 and a one year high of $9.33. The stock has a 50 day simple moving average of $5.09 and a 200 day simple moving average of $5.30.

Ardelyx (NASDAQ:ARDX - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.02. The business had revenue of $116.13 million during the quarter, compared to the consensus estimate of $111.16 million. Ardelyx had a negative net margin of 11.73% and a negative return on equity of 24.87%. Sell-side analysts predict that Ardelyx, Inc. will post -0.18 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have commented on ARDX shares. HC Wainwright reissued a "neutral" rating and set a $5.50 price objective on shares of Ardelyx in a report on Friday, February 21st. Raymond James reaffirmed a "strong-buy" rating and issued a $13.00 price target (down previously from $15.00) on shares of Ardelyx in a report on Friday, February 21st. Jefferies Financial Group lowered their price target on shares of Ardelyx from $11.00 to $8.00 and set a "buy" rating for the company in a report on Thursday, January 2nd. Cantor Fitzgerald raised shares of Ardelyx to a "strong-buy" rating in a report on Tuesday, March 4th. Finally, BTIG Research initiated coverage on shares of Ardelyx in a report on Tuesday, March 4th. They issued a "buy" rating and a $14.00 price target for the company. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, Ardelyx presently has an average rating of "Moderate Buy" and a consensus target price of $10.61.

Insider Buying and Selling at Ardelyx

In other Ardelyx news, CEO Michael Raab sold 41,666 shares of the company's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $5.36, for a total value of $223,329.76. Following the completion of the sale, the chief executive officer now directly owns 1,108,719 shares in the company, valued at approximately $5,942,733.84. This represents a 3.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Laura A. Williams sold 4,941 shares of the company's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $5.62, for a total value of $27,768.42. Following the completion of the sale, the insider now owns 303,804 shares of the company's stock, valued at $1,707,378.48. This represents a 1.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 158,076 shares of company stock valued at $823,804 in the last ninety days. Corporate insiders own 5.90% of the company's stock.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.